tradingkey.logo
๎™ผ
tradingkey.logo
๎™๊ฒ€์ƒ‰
๎™

Kalaris Therapeutics Inc

KLRS
๎˜ญ๊ด€์‹ฌ ๋ชฉ๋ก์— ์ถ”๊ฐ€
3.220USD
-0.025-0.77%
์ข…๊ฐ€ย 09-21 16:00๏ผˆET๏ผ‰
76.65M์‹œ๊ฐ€์ด์•ก
์†์‹คP/E TTM

KLRS ์žฌ๋ฌด ๋ฐ์ดํ„ฐ

์Šค๋งˆํŠธํ•œ ํˆฌ์ž์ž๋ฅผ ์œ„ํ•ด ์„ค๊ณ„๋œ ์˜ฌ์ธ์› ๋ฐ์ดํ„ฐ ๋Œ€์‹œ๋ณด๋“œ๋ฅผ ํ†ตํ•ด Kalaris Therapeutics Inc์˜ ์žฌ๋ฌด ๋ฐ์ดํ„ฐ๋ฅผ ํ™•์ธํ•˜์„ธ์š”. ๋ณต์žกํ•œ ์žฌ๋ฌด์ œํ‘œ๋ฅผ ์‚ฌ์šฉ์ž ์ •์˜ ๊ฐ€๋Šฅํ•œ ๋ทฐ๋กœ ๊ตฌ์„ฑํ•˜์—ฌ ์žฌ๋ฌด ๋ถ„์„์„ ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค. ์ตœ์‹  ์—ฐ๊ฐ„ ์žฌ๋ฌด ๋ณด๊ณ ์„œ์— ์ ‘๊ทผํ•˜๊ฑฐ๋‚˜, ์†์ต๊ณ„์‚ฐ์„œ, ์žฌ๋ฌด์ƒํƒœํ‘œ, ํ˜„๊ธˆ ํ๋ฆ„ํ‘œ๋ฅผ ์‚ฌ์šฉํ•˜์—ฌ ๋ถ„๊ธฐ๋ณ„ ์„ฑ๊ณผ๋ฅผ ๋ถ„์„ํ•˜์„ธ์š”. ์‹ค์‹œ๊ฐ„ ์žฌ๋ฌด ์ง€ํ‘œ๋ฅผ ์†๋์—์„œ ํ™•์ธํ•  ์ˆ˜ ์žˆ์–ด ํšŒ์‚ฌ์˜ ์‹œ์žฅ ๊ฑด์ „์„ฑ์„ ์‹œ๊ฐ„์— ๋”ฐ๋ผ ๊ทธ ์–ด๋А ๋•Œ๋ณด๋‹ค ์‰ฝ๊ฒŒ ๋ชจ๋‹ˆํ„ฐ๋งํ•  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.

ํ•ต์‹ฌ ์žฌ๋ฌด ๋น„์œจ

์‹œ๊ฐ€์ด์•ก
76.65M
๋ฐฐ๋‹น ์ˆ˜์ต๋ฅ 
0.00
P/E TTM
-4.09
์ฃผ๋‹น์ˆœ์ด์ต
-0.79
์ˆ˜์ต
--
์ˆœ์ด์ต
-58.77M
ROE
-66.60%
ROA
-41.43%

Kalaris Therapeutics Inc ์‹ค์  ๋ฐœํ‘œ์ผ๎˜

์ตœ์‹  ์ถœ์‹œ
Aug 11, 2026
EPS / ์˜ˆ์ƒ
-0.48/-0.50
์ˆ˜์ต / ์˜ˆ์ƒ
--/0.00

์žฌ๋ฌด์ œํ‘œ ์š”์•ฝ

๋ถ„๊ธฐ๋ณ„๎˜ฎ
๋ถ„๊ธฐ๋ณ„+์—ฐ๊ฐ„
๋ถ„๊ธฐ๋ณ„
์—ฐ๊ฐ„
FY2026Q2
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
์žฌ๋ฌด ์ง€ํ‘œ
EPS
20.27%-0.48
---0.46
---0.51
---0.64
---0.61
---2.52
----
----
----
----
----
----
----
----
----
----
----
----
----
----
์ˆ˜์ต
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
--0.00
----
์ˆœ์ด์ต
-1.45%-11.52M
-6.47%-10.86M
45.27%-10.00M
-188.27%-11.89M
-86.80%-11.35M
66.35%-10.20M
69.40%-18.27M
90.68%-4.13M
86.58%-6.08M
26.43%-30.30M
-56.53%-59.70M
-5.23%-44.27M
-1.41%-45.27M
6.11%-41.18M
34.18%-38.14M
7.55%-42.07M
-18.76%-44.64M
-41.85%-43.86M
-129.93%-57.94M
-92.72%-45.51M
๋ถ€์ฑ„๋น„์œจ
--32.22%
--29.21%
--26.35%
--39.51%
--0.00%
--0.00%
----
----
----
----
----
----
----
----
----
----
----
----
----
----
์ˆ˜์ต
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
--0.00
----
์˜์—… ์ด์ต
-1.06%-12.39M
-14.28%-11.83M
44.68%-10.80M
-126.02%-12.74M
-68.77%-12.26M
54.66%-10.35M
55.46%-19.52M
88.00%-5.64M
84.65%-7.26M
47.18%-22.84M
-8.41%-43.84M
-9.34%-46.96M
-6.01%-47.30M
-0.09%-43.23M
27.53%-40.43M
5.61%-42.95M
-18.51%-44.62M
-39.95%-43.19M
-119.53%-55.80M
-90.39%-45.50M
์ˆœ์ด์ต
-1.45%-11.52M
-6.47%-10.86M
45.27%-10.00M
-188.27%-11.89M
-86.80%-11.35M
66.35%-10.20M
69.40%-18.27M
90.68%-4.13M
86.58%-6.08M
26.43%-30.30M
-56.53%-59.70M
-5.23%-44.27M
-1.41%-45.27M
6.11%-41.18M
34.18%-38.14M
7.55%-42.07M
-18.76%-44.64M
-41.85%-43.86M
-129.93%-57.94M
-92.72%-45.51M
์œ ๋™์ž์‚ฐ
4.66%95.92M
-3.64%98.47M
0.22%118.81M
-36.19%78.18M
-29.47%91.65M
-27.78%102.18M
-36.82%118.55M
-44.31%122.53M
-48.62%129.94M
-33.35%141.48M
-22.80%187.63M
-19.12%220.02M
43.28%252.91M
2.83%212.28M
-4.06%243.05M
-3.49%272.04M
-44.15%176.52M
-39.22%206.44M
-29.88%253.35M
-26.58%281.87M
์œ ๋™ ๋ถ€์ฑ„ ์ด๊ณ„
14.21%8.74M
13.12%8.08M
85.42%9.71M
329.53%6.07M
224.33%7.65M
-6.71%7.14M
-81.53%5.24M
-95.73%1.41M
-92.28%2.36M
-69.33%7.66M
16.55%28.37M
59.59%33.07M
41.57%30.56M
33.91%24.96M
-35.70%24.34M
-14.29%20.72M
4.25%21.59M
20.25%18.64M
207.90%37.85M
78.78%24.17M
์ด ์ž์‚ฐ
7.21%99.54M
6.51%109.81M
2.69%121.74M
-33.75%81.17M
-29.12%92.84M
-28.48%103.09M
-37.87%118.55M
-50.65%122.53M
-53.66%130.99M
-40.94%144.14M
-31.14%190.80M
-15.45%248.31M
41.35%282.69M
5.61%244.04M
-3.32%277.08M
-7.21%293.70M
-38.93%200.00M
-34.22%231.09M
-22.71%286.59M
-19.60%316.53M
๋ถ€์ฑ„ ์ด๊ณ„
5.39%41.87M
5.18%41.25M
719.28%42.92M
2683.99%39.31M
271.45%39.73M
65.46%39.22M
-88.36%5.24M
-97.33%1.41M
-80.04%10.70M
-53.07%23.70M
-14.36%45.02M
30.90%52.98M
28.00%53.58M
28.15%50.51M
-14.30%52.56M
-17.78%40.47M
67.15%41.86M
88.48%39.41M
245.37%61.33M
148.53%49.23M
์ž๋ณธ ์ด๊ณ„
8.58%57.67M
7.33%68.56M
-30.44%78.81M
-65.43%41.87M
-55.84%53.12M
-46.97%63.87M
-22.28%113.31M
-37.99%121.12M
-47.50%120.29M
-37.77%120.44M
-35.07%145.78M
-22.86%195.33M
44.88%229.11M
0.97%193.53M
-0.33%224.52M
-5.27%253.23M
-47.72%158.14M
-41.98%191.68M
-36.20%225.27M
-28.51%267.30M
์ˆœ์˜์—…์ด์ต
11.91%-11.05M
-55.64%-11.58M
-97.84%-7.06M
-34.29%-11.33M
-10.78%-12.54M
83.23%-7.44M
88.39%-3.57M
75.52%-8.44M
58.27%-11.32M
-38.18%-44.38M
2.65%-30.73M
1.85%-34.48M
6.08%-27.12M
30.89%-32.12M
-12.48%-31.57M
3.60%-35.13M
-26.17%-28.88M
-145.57%-46.48M
-33.07%-28.07M
-101.79%-36.44M
์ˆœํˆฌ์ž
--20.17M
---50.35M
199.66%14.98M
-273.53%-34.71M
----
----
-80.17%5.00M
129.92%20.00M
-20.83%30.00M
-4.13%40.00M
86.29%25.22M
-73.38%-66.85M
8011.06%37.89M
175.89%41.72M
200.10%13.54M
-170.15%-38.56M
-100.60%-479.00K
-184.81%-54.98M
-803.59%-13.52M
126.14%54.97M
์ˆœ์žฌ๋ฌดํ™œ๋™
---377.00K
-101.58%-1.70M
--47.74M
--0.00
-100.00%0.00
--107.27M
-100.00%0.00
--0.00
-99.97%21.00K
----
-96.23%11.00K
-100.00%0.00
28786.89%70.48M
----
349.23%292.00K
75603.59%126.42M
--244.00K
--0.00
118.36%65.00K
-99.94%167.00K

์ˆ˜์ต๎˜

์‚ฌ์—…๋ณ„

์ฃผ๊ธฐ:
๋ฐ์ดํ„ฐ ์—†์Œ

์ง€์—ญ๋ณ„

์ฃผ๊ธฐ:
๋ฐ์ดํ„ฐ ์—†์Œ

์ž์ฃผ ๋ฌป๋Š” ์งˆ๋ฌธ

Kalaris Therapeutics Inc์˜ ์œ ๋™์ž์‚ฐ์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Kalaris Therapeutics Inc์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, ์œ ๋™์ž์‚ฐ์€ 118.81M์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” 0.22์ž…๋‹ˆ๋‹ค.

Kalaris Therapeutics Inc์˜ ์ด์ž์‚ฐ์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Kalaris Therapeutics Inc์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, Kalaris Therapeutics Inc์˜ ์ด์ž์‚ฐ์€ 121.74M์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” 2.69์ž…๋‹ˆ๋‹ค.

Kalaris Therapeutics Inc์˜ ์ด๋ถ€์ฑ„๋Š” ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Kalaris Therapeutics Inc์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, Kalaris Therapeutics Inc์˜ ์ด๋ถ€์ฑ„๋Š” 42.92M์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” 719.28์ž…๋‹ˆ๋‹ค.

Kalaris Therapeutics Inc์˜ ์ด์ž๋ณธ์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Kalaris Therapeutics Inc์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, Kalaris Therapeutics Inc์˜ ์ด์ž๋ณธ์€ 78.81M์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” -30.44์ž…๋‹ˆ๋‹ค.

Kalaris Therapeutics Inc์˜ ์ˆœ์˜์—…์†Œ๋“์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Kalaris Therapeutics Inc์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, Kalaris Therapeutics Inc์˜ ์ˆœ์˜์—…์†Œ๋“์€ -46.15M์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” 16.48์ž…๋‹ˆ๋‹ค.

Kalaris Therapeutics Inc์˜ ์ˆœํˆฌ์ž๋Š” ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Kalaris Therapeutics Inc์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, Kalaris Therapeutics Inc์˜ ์ˆœํˆฌ์ž๋Š” -19.72M์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” -120.76์ž…๋‹ˆ๋‹ค.

Kalaris Therapeutics Inc์˜ ์ˆœ์ž๊ธˆ์กฐ๋‹ฌ์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Kalaris Therapeutics Inc์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, Kalaris Therapeutics Inc์˜ ์ˆœ์ž๊ธˆ์กฐ๋‹ฌ์€ 155.01M์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” 738028.57์ž…๋‹ˆ๋‹ค.

Kalaris Therapeutics Inc์˜ ์ฃผ๋‹น์ˆœ์ด์ต(EPS)์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Kalaris Therapeutics Inc์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, ์ฃผ๋‹น์ˆœ์ด์ต(EPS)์€ -2.85์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” 98.95์ž…๋‹ˆ๋‹ค.

Kalaris Therapeutics Inc์˜ ์ˆœ์ด์ต์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Kalaris Therapeutics Inc์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, ์ˆœ์ด์ต์€ -43.44M์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” 26.09์ž…๋‹ˆ๋‹ค.

Kalaris Therapeutics Inc์˜ ์ž๊ธฐ์ž๋ณธ์ด์ต๋ฅ (ROE)์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Kalaris Therapeutics Inc์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, ์ž๊ธฐ์ž๋ณธ์ด์ต๋ฅ (ROE)์€ -45.22์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” 0.32์ž…๋‹ˆ๋‹ค.

Kalaris Therapeutics Inc์˜ ์ด์ž์‚ฐ์ด์ต๋ฅ (ROA)์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Kalaris Therapeutics Inc์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, ์ด์ž์‚ฐ์ด์ต๋ฅ (ROA)์€ -36.16์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” 4.84์ž…๋‹ˆ๋‹ค.

Kalaris Therapeutics Inc์˜ ์˜์—…์ด์ต์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Kalaris Therapeutics Inc์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, ์˜์—…์ด์ต์€ -46.15M์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” 16.48์ž…๋‹ˆ๋‹ค.
tradingkey.logo
์œ„ํ—˜ ๊ฒฝ๊ณ : ์ €ํฌ ์›น์‚ฌ์ดํŠธ์™€ ๋ชจ๋ฐ”์ผ ์•ฑ์€ ํŠน์ • ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ผ๋ฐ˜์ ์ธ ์ •๋ณด๋งŒ์„ ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค. Finsights๋Š” ์žฌ์ •์  ์กฐ์–ธ์ด๋‚˜ ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜์ง€ ์•Š์œผ๋ฉฐ, ์ด๋Ÿฌํ•œ ์ •๋ณด ์ œ๊ณต์ด Finsights๊ฐ€ ๊ธˆ์œต ์กฐ์–ธ์ด๋‚˜ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜๋Š” ๊ฒƒ์œผ๋กœ ํ•ด์„๋˜์–ด์„œ๋Š” ์•ˆ ๋ฉ๋‹ˆ๋‹ค.
ํˆฌ์ž ์ƒํ’ˆ์€ ํˆฌ์ž ์›๊ธˆ ์†์‹ค์„ ํฌํ•จํ•œ ์ƒ๋‹นํ•œ ํˆฌ์ž ์œ„ํ—˜์— ๋…ธ์ถœ๋˜์–ด ์žˆ์œผ๋ฉฐ, ๋ชจ๋“  ์‚ฌ๋žŒ์—๊ฒŒ ์ ํ•ฉํ•˜์ง€ ์•Š์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค. ํˆฌ์ž ์ƒํ’ˆ์˜ ๊ณผ๊ฑฐ ์„ฑ๊ณผ๋Š” ๋ฏธ๋ž˜ ์„ฑ๊ณผ๋ฅผ ๋ณด์žฅํ•˜์ง€ ์•Š์Šต๋‹ˆ๋‹ค.
Finsights๋Š” ์ œ3์ž ๊ด‘๊ณ ์ฃผ๋‚˜ ์ œํœด์‚ฌ๊ฐ€ ์ €ํฌ ์›น์‚ฌ์ดํŠธ๋‚˜ ๋ชจ๋ฐ”์ผ ์•ฑ ๋˜๋Š” ๊ทธ ์ผ๋ถ€์— ๊ด‘๊ณ ๋ฅผ ๊ฒŒ์žฌํ•˜๊ฑฐ๋‚˜ ์ „๋‹ฌํ•  ์ˆ˜ ์žˆ๋„๋ก ํ—ˆ์šฉํ•  ์ˆ˜ ์žˆ์œผ๋ฉฐ, ์‚ฌ์šฉ์ž๊ฐ€ ๊ด‘๊ณ ์™€ ์ƒํ˜ธ์ž‘์šฉํ•˜๋Š” ๋ฐฉ์‹์— ๋”ฐ๋ผ ์ด๋“ค๋กœ๋ถ€ํ„ฐ ๋ณด์ƒ์„ ๋ฐ›์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.
ยฉ ์ €์ž‘๊ถŒ: FINSIGHTS MEDIA PTE. LTD. ๋ชจ๋“  ๊ถŒ๋ฆฌ ๋ณด์œ